Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons in host defense

G R Foster1

  • 1Liver Unit, Imperial College School of Medicine at St. Mary's, London, England.

Seminars in Liver Disease
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Type I interferons are crucial for antiviral defense, initiating gene transcription via JAK/STAT pathways. Some viruses develop inhibitors to evade these crucial host defenses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department - uncovering the iceberg?

Epidemiology and infection·2018
Same author

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

Alimentary pharmacology & therapeutics·2017
Same author

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.

Journal of viral hepatitis·2017
Same author

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).

Journal of viral hepatitis·2017
Same author

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.

Alimentary pharmacology & therapeutics·2016
Same author

Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign.

HIV medicine·2016
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • Type I interferons are glycoproteins vital for host defense against viral infections.
  • Interferon binding to cell surface receptors triggers antiviral protein transcription.

Purpose of the Study:

  • To elucidate the mechanism of interferon-induced gene transcription.
  • To understand how viruses overcome interferon-mediated antiviral effects.

Main Methods:

  • The study focuses on the JAK/STAT signaling pathway.
  • It details the activation of protein kinases (JAK 1, Tyk 2) and STAT proteins.

Main Results:

  • Interferon signaling involves JAK 1 and Tyk 2 kinases activating STAT proteins.

Related Experiment Videos

  • These signaling molecules are shared with other cytokine pathways like erythropoietin and IL-2.
  • Viruses causing chronic infections have evolved inhibitors to counteract Type I interferons.

    • Conclusions:

    • The JAK/STAT pathway is central to Type I interferon's antiviral action.
    • Viruses employ inhibitory strategies to compromise interferon effectiveness, impacting chronic infections.